A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil

Urology

Volumn 48, Issue 6, 1996, Pages 851-856

  Hellstrom, Wayne J G ^b   Bennett, Alan H ^b   Gesundheit, Neil ^b   Kaiser, Fran E ^b   Lue, Tom F ^b   Padma Nathan, Harin ^b   Peterson, Craig A ^b   Tam, Peter Y ^b   Todd, Leslie K ^b   Varady, John C ^b   Place, Virgil A ^a  

^a Menlo Park and VIVUS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

ADULT; AGED; ALPROSTADIL; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SELF ADMINISTRATION; URETHRA; VASODILATOR AGENTS;

EID: 0344936336     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00428-1     Document Type: Article

References (23)

1. NIH Consensus Conference: Impotence: NIH Consensus Development Panel on Impotence. JAMA 270: 83-90, 1993.
2. Krane RJ, Goldstein I, and Saenz de Tejada I: Impotence. N Engl J Med 321: 1648-1659, 1989.
3. Virag R, Shoukry K, Floresco J, Nollet F, and Greco E: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 145: 287-293, 1991.
4. Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, and Schover LR: Intracavernous injection therapy: analysis of results and complications. J Urol 143: 1138-1141, 1990.
5. Linet OI, and Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334: 873-877, 1996.
6. Giuliano F, Blanchet P, Banzet O, Lancrenon S, Benoit G, and Jardin A: Erection disorders: efficacy and tolerability after 6 months of intracavernous self-injections of alprostadil. Groupe Francais d'Etude de l'Alprostadil. Presse Med 23: 1516-1521, 1994.
7. Yohimbine for male sexual dysfunction. Med Lett Drugs Ther 36: 115-116, 1994.
8. Morales A: Nonsurgical management options in impotence. Hosp Pract 28: 15-16, 19-20, 23-24, 1993.
9. Meinhardt W, Lycklama a Nijeholt AAB, Kropman RF, and Zwartendijk J: The negative pressure device for erectile disorders: when does it fail? J Urol 149: 1285-1287, 1993.
10. Broderick GA, McGahan JP, Stone AR, and White RD: The hemodynamics of vacuum constriction erections: assessment by color Doppler ultrasound. J Urol 147: 57-61, 1992.
11. Cookson MS, Phillips DL, Huff ME, and Fitch WP III: Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol 149: 1308-1312, 1993.
12. Rossi D, Rattier C, Belicar M, Bladou F, Hermanowicz M, Coulange C, and Serment G: The inflatable penile pros-thesis: experiences apropos of 58 implants. Prog Urol 3: 796-802, 1993.
13. Bejany DE, Perito PE, Lustgarten M, and Rhamy RK: Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature. J Urol 150: 190-192, 1993.
14. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, and Resnick M: Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 15: 121-129, 1989.
15. Irwin MB, and Kata EJ: High attrition rate with intracavernous injection of prostaglandin El for impotency. Urology 43: 84-87, 1994.
16. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, and Resnick MI: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141: 54-57, 1989.
17. Kerfoot WW, and Carson CC: Pharmacologically induced erections among geriatric men. J Urol 146: 1022-1024, 1991.
18. Padma-Nathan H, Goldstein I, Payton T, and Krane RJ: Intracavernosal pharmacotherapy: the pharmacologic erection program. World J Urol 5: 160-165, 1987.
19. Waldhauser M, and Schramek P: Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction. J Urol 140: 525-527, 1988.
20. Padma-Nathan H, Keller T, Poppiti R, Lue TF, Tam P, and Place V: Hemodynamic effects of intraurethral alprostadil: the medicated urethral system for erection (MUSE). J Urol 151: 469, 1994.
21. Padma-Nathan H, Bennett AH, Gesundheit N, Hellstrom W, Henry D, Lue TF, Morley JE, Peterson C, Prendergast JJ, Tam P, et al: Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE). J Urol 153: 473A, 1995.
22. Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kubota Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M, and Shirai M: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 141: 323-325, 1989.
23. Wolfson B, Pickett S, Scott NE, DeKernion JB, and Rajfer J: Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 42: 73-75, 1993.